Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹8,374 Cr
Revenue (TTM)
₹2,126 Cr
Net Profit (TTM)
₹77 Cr
ROE
5.4 %
ROCE
9.3 %
P/E Ratio
109
P/B Ratio
9.3
Industry P/E
63.93
EV/EBITDA
24.9
Div. Yield
0 %
Debt to Equity
0.7
Book Value
₹20.6
EPS
₹3
Face value
2
Shares outstanding
436,850,810
CFO
₹545.46 Cr
EBITDA
₹1,027.91 Cr
Net Profit
₹147.17 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sequent Scientific
| -9.0 | -15.3 | -9.4 | 36.3 | 37.5 | -3.3 | 3.7 |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sequent Scientific
| 12.9 | 52.7 | 29.9 | -45.6 | -5.3 | 139.1 | 4.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sequent Scientific
|
189.7 | 8,374.4 | 2,125.5 | 96.1 | 10.6 | 13.3 | 109 | 9.3 |
| 2,943.9 | 36,792.9 | 5,201.6 | 1,014.6 | 22.9 | 25 | 36.3 | 8.0 | |
| 8,370.5 | 21,081.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 104.9 | 25.4 | |
| 1,470.8 | 28,023.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 32.2 | 5.6 | |
| 1,422.9 | 1,200.0 | 314.4 | 36.7 | 17.3 | 12.6 | 29.3 | 3.5 | |
| 2,084.9 | 33,495.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 44.4 | 8.4 | |
| 2,203.6 | 1,360.7 | 446.9 | 35.1 | 8.7 | 12 | 38.8 | 4.3 | |
| 4,724.5 | 21,608.7 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.3 | 5.4 | |
| 135.7 | 18,084.4 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.3 | |
| 1,187.3 | 19,377.2 | 3,151.0 | -10.0 | 8.4 | 2.5 | 880.8 | 4.2 |
No Review & Analysis are available.
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable... alkaloids; Read more
Incorporated
1985
Chairman
Kamal K Sharma
Managing Director
Rajaram Narayanan
Group
Sequent
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Sequent Scientific Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Sequent Scientific Ltd is ₹189.71 (NSE) and ₹189.00 (BSE) as of 19-Mar-2026 15:59 IST. Sequent Scientific Ltd has given a return of 37.52% in the last 3 years.
The P/E ratio of Sequent Scientific Ltd is 109.03 times as on 19-Mar-2026, a 71 premium to its peers’ median range of 63.93 times.
The P/B ratio of Sequent Scientific Ltd is 9.31 times as on 19-Mar-2026, a 9 discount to its peers’ median range of 10.20 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
149.64
|
5.39
|
|
2024
|
0.00
|
4.96
|
|
2023
|
0.00
|
2.82
|
|
2022
|
81.14
|
5.15
|
|
2021
|
62.69
|
8.31
|
The 52-week high and low of Sequent Scientific Ltd are Rs 257.85 and Rs 117.35 as of 19-Mar-2026.
Sequent Scientific Ltd has a market capitalisation of ₹ 8,374 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sequent Scientific Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-5.61
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.